Frederik F. Kreiner

Soborg, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801].

Journal: Molecular metabolism

Published: September 08, 2024

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives.

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives.

Journal: Biomedicines

Published: August 11, 2023

Molecular engineering of insulin for recombinant expression in yeast.

Molecular engineering of insulin for recombinant expression in yeast.

Journal: Trends in biotechnology

Published: August 10, 2023

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.

Journal: Molecular metabolism

Published: June 16, 2023

Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.

Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.

Journal: Aging cell

Published: January 25, 2023

Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.

Liraglutide protects β-cells in novel human islet spheroid models of type 1 diabetes.

Journal: Clinical immunology (Orlando, Fla.)

Published: August 30, 2022

The potential of glucagon-like peptide-1 receptor agonists in heart failure.

The potential of glucagon-like peptide-1 receptor agonists in heart failure.

Journal: Frontiers in physiology

Published: July 01, 2022

Induction of antigenic immune tolerance to delay type 1 diabetes - challenges for clinical translation.

Induction of antigenic immune tolerance to delay type 1 diabetes - challenges for clinical translation.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: July 01, 2022

Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives.

Interleukin 6 in diabetes, chronic kidney disease, and cardiovascular disease: mechanisms and therapeutic perspectives.

Journal: Expert review of clinical immunology

Published: February 25, 2022

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.

Journal: Therapeutic advances in endocrinology and metabolism

Published: February 01, 2022

Current state of antigen-specific immunotherapy for type 1 diabetes.

Current state of antigen-specific immunotherapy for type 1 diabetes.

Journal: Current opinion in endocrinology, diabetes, and obesity

Published: June 08, 2021

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.

Journal: Diabetes, obesity & metabolism

Published: May 27, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026